Ardelyx sells IBSRELA and XPHOZAH, prescription medicines for irritable bowel syndrome and elevated phosphorus in dialysis patients. It last closed at $3.18 on Nov 17, up 3.58% on the day. In the past 30 days there were 2 dark pool prints totaling $567K, the largest $348K.
Only 1 firm rated ARDX in the past 90 days, not enough for a consensus
Average 12-month target
$11.00
▲ 245.9% upside
Based on 1 analyst who set a price target on ARDX in the past 90 days. The average target is $11.00, with a high of $11.00 and a low of $11.00, compared with the last close of $3.18.
Highest target$11.00
Average target$11.00
Lowest target$11.00
Latest rating changes
BTIGTarget lowered
Nov 10Buy$14 → $11
WedbushReiterated
Aug 19Buy$9
WedbushReiterated
Aug 18Buy$9
Piper SandlerMaintained
Aug 17Buy$15
CitigroupMaintained
Aug 10Buy$11
Date
Firm
Action
Rating
Price target
Nov 10
BTIG
Target lowered
Buy
$14 → $11
Aug 19
Wedbush
Reiterated
Buy
$9
Aug 18
Wedbush
Reiterated
Buy
$9
Aug 17
Piper Sandler
Maintained
Buy
$15
Aug 10
Citigroup
Maintained
Buy
$11
Loading…
Technical Analysis
ARDX · as of the Nov 17 close · updated after every close
Moving sideways
The stock sits between its 20 and 50 day averages. It is 59% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 52). The nearest support is the Pivot at $3.14, and the nearest resistance the Pivot R1 at $3.23.
Short trendNeutral
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 4.7%/day
Key levels
$8.4052 week high+164.2%
$5.06200 day average+59.1%
$3.92100 day average+23.3%
$3.35Swing high (Oct 15)+5.3%
$3.2550 day average+2.2%
$3.23Pivot R1+1.6%
$3.18Last close
$3.14Pivot−1.3%
$3.09Pivot S1−2.8%
$3.0720 day average−3.5%
$3.05Swing low (Oct 19)−4.1%
$2.8052 week low−11.9%
Indicators
RSI (14)
51.97
Middle of its range
Neutral
MACD
-0.05
Above its signal line
Bullish
Stochastic
52.2
Middle of its range
Neutral
ADX (14)
18.0
No clear trend
Williams %R
-36.7
Oversold below −80, overbought above −20
Neutral
CCI (20)
77.5
Oversold below −100, overbought above 100
Neutral
Rate of change
+5.0%
Change over 10 sessions
Bullish
ATR (14)
$0.15
Typical daily range, 4.7% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityLow, 12.6%/day
Key levels
$8.4052 week high+164.2%
$5.06200 day average+59.1%
$3.92100 day average+23.3%
$3.35Swing high (Oct 15)+5.3%
$3.2550 day average+2.2%
$3.23Pivot R1+1.6%
$3.18Last close
$3.14Pivot−1.3%
$3.09Pivot S1−2.8%
$3.0720 day average−3.5%
$3.05Swing low (Oct 19)−4.1%
$2.8052 week low−11.9%
Indicators
RSI (14)
31.99
Weak, oversold below 30
Neutral
MACD
-0.66
Below its signal line
Bearish
Stochastic
17.7
Near the bottom of its range
Oversold
ADX (14)
34.5
Trending down
Williams %R
-70.5
Oversold below −80, overbought above −20
Neutral
CCI (20)
-72.8
Oversold below −100, overbought above 100
Neutral
Rate of change
−11.2%
Change over 10 sessions
Bearish
ATR (14)
$0.40
Typical daily range, 12.6% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ARDX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ARDX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow ARDX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ARDX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARDX is in one of them and how their past ARDX trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Ardelyx
Ardelyx is a biopharmaceutical company based in Fremont, California. It sells two prescription medicines, both made from the active ingredient tenapanor. IBSRELA treats adults with irritable bowel syndrome with constipation, and XPHOZAH lowers phosphorus levels in adults with chronic kidney disease who are on dialysis. The company sells these medicines in the United States and is also studying tenapanor for chronic idiopathic constipation.